HER2+ breast cancer? That’ll be $15,000 please
Women with HER2 positive metastatic breast cancer are missing out on best treatment because the drugs are not on the PBS, says a group of eminent oncologists.
Their review of 100 trials of systemic treatments for HER2+ metastatic breast cancer paints a largely upbeat picture in which the recent development of targeted drugs has significantly improved survival for women diagnosed with this aggressive disease.
There were reports of increasing numbers of women alive and well more than five years on from diagnosis of metastatic disease